News & Media
- Press Releases
Abstracts/Posters & Publications
Posters & Publications
DURATA ANNOUNCES A PHASE I, OPEN-LABEL, SINGLE DOSE STUDY TO INVESTIGATE THE PHARMACOKINETICS (PK), SAFTY AND TOLERABILITY OF DALBANVANCIN IN ADOLESCENTS AGE 12 TO 17, RECEIVING STANDARD INTRAVENOUS ANTI-INFECTIVE TREATMENT FOR BATERIAL INFECTIONS
MORRISTOWN, N.J. -- September 19, 2011 -- Durata Therapeutics presented a poster titled, “A phase I, Open-Label, Single Dose Study to investigate the pharmacokinetics (PK), Safty and tolerability of Dalbanvancin in adolescents age 12 to 17 years.” The poster was presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in Chicago. View Poster
DURATA ANNOUNCES ANTIBIOTIC SURVEILLANCE RESULTS FOR DALBAVANCIN PRESENTED AT ECCMID MEETING
MORRISTOWN, N.J. -- May 10, 2011 -- Durata Therapeutics today announced surveillance data demonstrating potency of the Company’s lead antibiotic product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide, against a broad spectrum of gram-positive bacteria prevalent in recent years. The surveillance data also confirmed that the susceptibility profile of dalbavancin has not changed since surveillance studies were first initiated over a decade ago. View Poster 1 View Poster 2
DURATA ANNOUNCES SUPPORTIVE DATA ANALYSIS FROM PHASE 3 DALBAVANCIN TRIAL AT ECCMID MEETING
MORRISTOWN, N.J. --(BUSINESS WIRE) -- May 09, 2011 -- Durata Therapeutics today announced supportive, retrospective data from a previously completed global, Phase 3 study of the Company’s lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide. As reported in a poster presentation titled, “Dalbavancin vs Linezolid for Treatment of Acute Bacterial Infections of the Skin: A Comparison of Early and Standard Outcome Measures in Study VER001-9”, a reanalysis of data from that Phase 3 study demonstrated that clinical efficacy associated with dalbavancin was again similar to linezolid, in these analyses based on both resolution of fever and cessation of spread of the lesion within a 48- to 96-hour period after the start of therapy. Recently, the Food and Drug Administration (FDA) issued new draft guidance establishing that antibiotic effectiveness be assessed between 48 and 72 hours following initiation of therapy. View Poster